Avacincaptad pegol shows significant reduction in GA lesion growth over two years
Izervay (avacincaptad pegol intravitreal solution; Astellas Pharma) demonstrated positive results in the GATHER2 Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), according to data presented at AAO 2023.
The study showed that Izervay, administered either every month or every-other-month, significantly reduced the rate of GA lesion growth compared to a sham treatment over the course of two years. In addition, Izervay was well-tolerated with only minor cases of side effects reported.
Although the trial did not meet the specific objective related to vision loss, these findings represent a significant advancement in the treatment of GA associated with AMD, providing hope for improved outcomes for patients in the future.
Read the full press release from Astellas here.